Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7956544 | 0.86 | KMT2A (0.72) | KMT2ALMNASMN1; SMN2TSHRPOLB | |
| SCHEMBL1142036 | 0.86 | MAPT (0.57) | KMT2ASMN1; SMN2POLBBRD4HSD17B10 | |
| SCHEMBL248401 | 0.82 | KMT2A (0.66) | KMT2ALMNASMN1; SMN2TSHRPOLB | |
| SCHEMBL249215 | 0.81 | KMT2A (0.51) | KMT2ALMNASMN1; SMN2TSHRPOLB | |
| SCHEMBL14625066 | 0.81 | KMT2A (0.64) | KMT2ALMNASMN1; SMN2TSHRPOLB | |
| SCHEMBL11482525 | 0.81 | KMT2A (0.64) | KMT2ALMNASMN1; SMN2TSHRPOLB | |
| SCHEMBL7952997 | 0.81 | KMT2A (0.64) | KMT2ALMNASMN1; SMN2TSHRPOLB | |
| SCHEMBL7959649 | 0.78 | RAB9A (0.67) | KMT2ALMNASMN1; SMN2TSHRPOLB | |
| SCHEMBL1142084 | 0.78 | BRD4 (0.78) | KMT2ALMNASMN1; SMN2BRD4MAPK1 | |
| SCHEMBL1141399 | 0.78 | P2RX7 (0.53) | KMT2ASMN1; SMN2TSHRBRD4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1679308-B1 | NOVEL INDAZOLE DERIVATIVE | UBE INDUSTRIES (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8252945-B2 | Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient | UBE INDUSTRIES, LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2468729-A1 | Novel indazole derivative | UBE INDUSTRIES, LTD. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
| US-7855222-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7563906-B2 | Indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090012123-A1 | Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1870099-A1 | PROTECTIVE AGENT FOR RETINAL NEURONAL CELL COMPRISING INDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | Ube Industries, Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | KMT2A 3278/4885LMNA 1711/4885SMN1; SMN2 851/4885 |
| US-20070129404-A1 | Novel indazole derivatives | CIT, ROCK1, ROCK2 | KMT2A 3055/4885LMNA 4185/4885SMN1; SMN2 4865/4885 |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, ROCK2 | KMT2A 3282/4885LMNA 1762/4885SMN1; SMN2 885/4885 |
| US-20090012123-A1 | Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient | GRIK3, ALDH1A2, GRIN3A | KMT2A 3950/4885LMNA 2895/4885SMN1; SMN2 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.